1. Development and validation of a LC–MS/MS method for the quantification of tenofovir and emtricitabine in seminal plasma
- Author
-
J.P. Wolf, Elodie Valade, Sílvia M. Illamola, Yi Zheng, Jean-Marc Tréluyer, E. Dulioust, and Déborah Hirt
- Subjects
Male ,Electrospray ,Tenofovir ,Formic acid ,Clinical Biochemistry ,Analytical chemistry ,Tandem mass spectrometry ,Emtricitabine ,030226 pharmacology & pharmacy ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Drug Stability ,Limit of Detection ,Semen ,Tandem Mass Spectrometry ,Lc ms ms ,medicine ,Humans ,Chromatography ,Chemistry ,010401 analytical chemistry ,Reproducibility of Results ,Cell Biology ,General Medicine ,Plasma ,Reference Standards ,0104 chemical sciences ,Chromatography, Liquid ,medicine.drug - Abstract
Accurate and sensitive liquid-chromatography tandem mass spectrometry method for the quantification of tenofovir and emtricitabine in seminal plasma has been developed and full validated. Molecules were separated by high-performance liquid chromatography on an Atlantis T3 C18 column using a gradient of deionized water and methanol, including 0.05% formic acid (250μl/min) and detected by electrospray ionisation/tandem mass spectrometry in positive ion mode. The method was validated over a clinical range of 3.13-1000ng/mL for tenofovir and 6.25-2000ng/mL for emtricitabine. Inter and intra-assay precisions were 9.37% for tenofovir and10.88% for emtricitabine, and accuracies were between 0.48% and 8.43% for tenofovir, and between 0.64% and 13.87% for emtricitabine. The developed method was successfully applied for analysing tenofovir and emtricitabine concentrations in seminal plasma samples from a clinical study. The use of tandem mass spectrometry can be a suitable method for the analysis of this kind of matrices, providing high sensitivity and specificity to the analysis.
- Published
- 2016
- Full Text
- View/download PDF